Stock 4568 DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-25 am EDT 		5-day change 1st Jan Change
4,766 JPY +0.78% Intraday chart for Daiichi Sankyo Co., Ltd. +7.27% +23.09%
Apr. 25 Scholz pledges further support for the pharmaceutical industry DP
Apr. 25 Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scholz pledges further support for the pharmaceutical industry
DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
MT
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB
PU
Daiichi Sankyo : FY2023 Reference Dat
PU
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.
CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.
CI
Middle East Tensions Dent Asian Stock Markets
MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication
MT
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours
AQ
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
MT
AstraZeneca: US approval extended for Enhertu
CF
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval
MT
Astra hails neurology data; CVS flags cyberattack
AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval
AN
AstraZeneca Wins US Approval for Solid Tumor Treatment
MT
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB
PU
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.